| Entry |
|
|---|
| Name |
Prasugrel hydrochloride (JAN/USAN);
Effient (TN)
|
|---|
| Product |
|
|---|
| Generic |
PRASUGREL (A-S Medication Solutions), PRASUGREL (Accord Healthcare), PRASUGREL (American Health Packaging), PRASUGREL (Amneal Pharmaceuticals LLC), PRASUGREL (Apotex Corp.), PRASUGREL (Ascend Laboratories), PRASUGREL (Aurobindo Pharma Limited), PRASUGREL (Golden State Medical Supply), PRASUGREL (Liberty Pharmaceuticals), PRASUGREL (Mylan Pharmaceuticals), PRASUGREL (Panacea Biotec), PRASUGREL (Sunshine Lake Pharma) |
|---|
| Formula |
C20H20FNO3S. HCl
|
|---|
| Exact mass |
409.0915
|
|---|
| Mol weight |
409.902
|
|---|
| Structure |
   |
|---|
| Class |
|
|---|
| Remark |
| Therapeutic category: | 3399 |
|
|---|
| Efficacy |
Platelet aggregation inhibitor, Purinergic receptor P2Y12 antagonist |
|---|
| Disease |
Unstable angina [DS: H01632] Myocardial infarction [DS: H01730] |
|---|
| Comment |
Thienopyridine derivative
|
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Metabolism |
|
|---|
| Interaction |
CYP inhibition: CYP2B6 [HSA: 1555]
 |
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
B BLOOD AND BLOOD FORMING ORGANS
B01 ANTITHROMBOTIC AGENTS
B01A ANTITHROMBOTIC AGENTS
B01AC Platelet aggregation inhibitors excl. heparin
B01AC22 Prasugrel
D05597 Prasugrel hydrochloride (JAN/USAN) <JP/US>
USP drug classification [BR:br08302]
Blood Products and Modifiers
Platelet Modifying Agents
Adenosine Diphosphate P2Y12
Prasugrel
D05597 Prasugrel hydrochloride (JAN/USAN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
33 Blood and body fluid agents
339 Miscellaneous
3399 Others
D05597 Prasugrel hydrochloride (JAN/USAN)
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Purine / pyrimidine
P2RY12
D05597 Prasugrel hydrochloride (JAN/USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D05597
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D05597
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D05597
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D05597
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
D05597
 |
|---|
| Other DBs |
|
|---|
| LinkDB |
 |
|---|
| KCF data |
ATOM 27
1 N1y N 17.0100 -15.7500
2 C1x C 17.0100 -14.3500
3 C1x C 18.2000 -13.6500
4 C8y C 19.4600 -14.3500
5 C8y C 19.4600 -15.7500
6 C1x C 18.2000 -16.4500
7 S2x S 20.7900 -13.9300
8 C8y C 21.5600 -15.0500
9 C8x C 20.7900 -16.1700
10 O7a O 22.9600 -15.0500
11 C7a C 23.6600 -13.8600
12 C1a C 25.0600 -13.8600
13 O6a O 22.9600 -12.6700
14 C1c C 15.8200 -16.4500
15 C8y C 14.6300 -15.7500
16 C5a C 15.8200 -17.8500
17 O5a O 17.0100 -18.5500
18 C1y C 14.6300 -18.5500
19 C8y C 14.6300 -14.3500
20 C8x C 13.3700 -13.6500
21 C8x C 12.1800 -14.3500
22 C8x C 12.1800 -15.7500
23 C8x C 13.3700 -16.4500
24 C1x C 13.2300 -18.5500
25 C1x C 13.9300 -19.7400
26 X F 15.8200 -13.6500
27 X Cl 24.7800 -18.0600
BOND 29
1 1 2 1
2 2 3 1
3 3 4 1
4 4 5 2
5 5 6 1
6 1 6 1
7 4 7 1
8 7 8 1
9 8 9 2
10 5 9 1
11 8 10 1
12 10 11 1
13 11 12 1
14 11 13 2
15 1 14 1
16 14 15 1
17 14 16 1
18 16 17 2
19 16 18 1
20 15 19 2
21 19 20 1
22 20 21 2
23 21 22 1
24 22 23 2
25 15 23 1
26 18 24 1
27 24 25 1
28 25 18 1
29 19 26 1
|
|---|
